Pioglitazone does not affect the risk of kidney cancer in patients with type 2 diabetes

Metabolism: Clinical and Experimental

Volumn 63, Issue 8, 2014, Pages 1049-1055

  Tseng, Chin Hsiao ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Asian population; Cohort study; Epidemiology; Insurance database; Taiwan

Indexed keywords

ACARBOSE; INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; DATA BASE; DISEASE ASSOCIATION; DOSE RESPONSE; FEMALE; FOLLOW UP; HUMAN; KIDNEY CANCER; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH INSURANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REIMBURSEMENT; TAIWAN; TREATMENT DURATION;

ASIAN POPULATION; COHORT STUDY; EPIDEMIOLOGY; INSURANCE DATABASE; TAIWAN;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 84904401409     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2014.04.014     Document Type: Article

References (49)

1. B. Ljungberg, S.C. Campbell, and H.Y. Choi et al. The epidemiology of renal cell carcinoma Eur Urol 60 4 2011 615 621
2. P. Vigneri, F. Frasca, and L. Sciacca et al. Diabetes and cancer Endocr Relat Cancer 16 4 2009 1103 1123
3. M.Y. Lee, K.D. Lin, and P.J. Hsiao et al. The association of diabetes mellitus with liver, colon, lung, and prostate cancer is independent of hypertension, hyperlipidemia, and gout in Taiwanese patients Metabolism 61 2 2012 242 249
4. C.H. Tseng Diabetes, insulin use, and non-Hodgkin lymphoma mortality in Taiwan Metabolism 61 7 2012 1003 1009
5. C.H. Tseng Diabetes and risk of prostate cancer: A study using the National Health Insurance Diabetes Care 34 3 2011 616 621
6. C.H. Tseng Diabetes and risk of bladder cancer: A study using the National Health Insurance database in Taiwan Diabetologia 54 8 2011 2009 2015
7. V. Rosato, A. Tavani, and C. Bosetti et al. Metabolic syndrome and pancreatic cancer risk: a case-control study in Italy and meta-analysis Metabolism 60 10 2011 1372 1378
8. C.E. Matthews, X. Sui, and M.J. LaMonte et al. Metabolic syndrome and risk of death from cancers of the digestive system Metabolism 59 8 2010 1231 1239
9. S. Sen, Y. He, and D. Koya et al. Cancer biology in diabetes J Diabetes Invest 5 3 2014 251 264
10. S.C. Larsson, and A. Wolk Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies Diabetologia 54 5 2011 1013 1018
11. M. Washio, M. Mori, and K. Mikami et al. Cigarette smoking and other risk factors for kidney cancer death in a Japanese population: Japan Collaborative Cohort Study for evaluation of cancer risk (JACC study) Asian Pac J Cancer Prev 14 11 2013 6523 6528
12. X.S. Song, B. Fan, and C. Ma et al. Clinical research on the correlations between type 2 diabetes mellitus and renal clear cell carcinoma Zhonghua Wai Ke Za Zhi 51 7 2013 627 630 [Chinese]
13. C. Bao, X. Yang, and W. Xu et al. Diabetes mellitus and incidence and mortality of kidney cancer: a meta-analysis J Diabetes Complications 27 4 2013 357 364
14. B. Thakkar, K.N. Aronis, and M.T. Vamvini et al. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies Metabolism 62 7 2013 922 934
15. D.M. Baur, J. Klotsche, and O.P. Hamnvik et al. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort Metabolism 60 10 2011 1363 1371
16. A.E. Buchs, and B.G. Silverman Incidence of malignancies in patients with diabetes mellitus and correlation with treatment modalities in a large Israeli health maintenance organization: a historical cohort study Metabolism 60 10 2011 1379 1385
17. C. La Vecchia Diabetes mellitus, medications for type 2 diabetes mellitus, and cancer risk Metabolism 60 10 2011 1357 1358
18. M. Inaba, Y. Otani, and K. Nishimura et al. Marked hyperglycemia after androgen-deprivation therapy for prostate cancer and usefulness of pioglitazone for its treatment Metabolism 54 1 2005 55 59 (Pubitemid 39572457)
19. C.H. Tseng, and F.H. Tseng Diabetes and gastric cancer: the potential links World J Gastroenterol 20 7 2014 1701 1711
20. J. Yuan, A. Takahashi, and N. Masumori et al. Ligands for peroxisome proliferator-activated receptor gamma have potent antitumor effect against human renal cell carcinoma Urology 65 3 2005 594 599 (Pubitemid 40386032)
21. K. Inoue, Y. Kawahito, and Y. Tsubouchi et al. Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists Biochem Biophys Res Commun 287 3 2001 727 732 (Pubitemid 32912775)
22. B. Walter, I. Schrettenbrunner, and M. Vogelhuber et al. Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial Med Oncol 29 2 2012 799 805
23. A. Ferrara, J.D. Lewis, and C.P. Quesenberry Jr. et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes Diabetes Care 34 4 2011 923 929
24. A. Neumann, A. Weill, and P. Ricordeau et al. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study Diabetologia 55 7 2012 1953 1962
25. I.N. Colmers, S.L. Bowker, and J.A. Johnson Thiazolidinedione use and cancer incidence in type 2 diabetes: A systematic review and meta-analysis Diabetes Metab 38 6 2012 475 484
26. C.H. Tseng A review on thiazolidinediones and bladder cancer in human studies J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 32 1 2014 1 45
27. J.D. Lewis, A. Ferrara, and T. Peng et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study Diabetes Care 34 4 2011 916 922
28. J.A. Dormandy, B. Charbonnel, and D.J. Eckland et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 366 9493 2005 1279 1289 (Pubitemid 41416583)
29. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 24 2007 2457 2471 (Pubitemid 46919772)
30. C.H. Tseng Thyroid cancer risk is not increased in diabetic patients PLoS One 7 12 2012 e53096
31. C.H. Tseng Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in Taiwan BMC Cancer 13 2013 7
32. C.H. Tseng Rosiglitazone is not associated with an increased risk of bladder cancer Cancer Epidemiol 37 4 2013 385 389
33. C.H. Tseng Diabetes is not an independent risk factor for hepatocellular carcinoma Diabetes Metab Res Rev 29 7 2013 515 524
34. C.H. Tseng Human insulin does not increase prostate cancer risk in Taiwanese Clin Genitourin Cancer 12 1 2014 e7 e12
35. Department of Biostatistics, Vanderbilt University PS: Power and Sample Size Calculation, version 3.0.43, 2011, by William D. Dupont and Walton D. Plummer, Jr. http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/ PowerSampleSize [last accessed March 20, 2014]
36. C.H. Tseng Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities? J Formos Med Assoc 111 3 2012 123 131
37. C.H. Tseng, and F.H. Tseng Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 30 4 2012 368 402
38. C.H. Tseng Pioglitazone and bladder cancer: a population-based study of Taiwanese Diabetes Care 35 2 2012 278 280
39. W.H. Chow, L.M. Dong, and S.S. Devesa Epidemiology and risk factors for kidney cancer Nat Rev Urol 7 5 2010 245 257
40. S.W. Lai, K.F. Liao, and H.C. Lai et al. Kidney cancer and diabetes mellitus: a population-based case-control study in Taiwan Ann Acad Med Singapore 42 3 2013 120 124
41. K.J. van Stralen, F.W. Dekker, and C. Zoccali et al. Confounding Nephron Clin Pract 116 2 2010 c143 c147
42. D.Y. Song, S. Song, and Y. Song et al. Alcohol intake and renal cell cancer risk: a meta-analysis Br J Cancer 106 11 2012 1881 1890
43. G. Wang, J. Hou, and L. Ma et al. Risk factor for clear cell renal cell carcinoma in Chinese population: a case-control study Cancer Epidemiol 36 2 2012 177 182
44. N.B. Haas, and K.L. Nathanson Hereditary kidney cancer syndromes Adv Chronic Kidney Dis 21 1 2014 81 90
45. X. Wang, X. Guo, and W. Yu et al. Expression of methionine adenosyltransferase 2A in renal cell carcinomas and potential mechanism for kidney carcinogenesis BMC Cancer 14 2014 196
46. O. Oz Gul, E. Tuncel, and Y. Yilmaz et al. Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients Metabolism 59 1 2010 64 69
47. C.H. Tseng, and T.S. Huang Pioglitazone with sulfonylurea: Glycemic and lipid effects in Taiwanese type 2 diabetic patients Diabetes Res Clin Pract 70 2 2005 193 194
48. A.H. Barnett Redefining the role of thiazolidinediones in the management of type 2 diabetes Vasc Health Risk Manag 5 1 2009 141 151
49. R.B. Goldberg, D.M. Kendall, and M.A. Deeg et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia Diabetes Care 28 7 2005 1547 1554 (Pubitemid 40923063)